Basic research in 2019 yielded exciting discoveries and advancements in thyroidology. Specifically, there have been breakthroughs in our understanding of the molecular actions of thyroid hormone and thyroid hormone receptors, thyroid hormone metabolism and transport, autoimmunity, and thyroid cancer. Next, I summarize important studies published over the past year and whose major data I presented during the 89th American Thyroid Association annual meeting at the opening plenary session The Year in Thyroidology.
CrantzFR, SilvaJE, LarsenPR. 1982. An analysis of the sources and quantity of 3,5,3'-triiodothyronine specifically bound to nuclear receptors in rat cerebral cortex and cerebellum. Endocrinology, 110:367–375.
7.
BoccoBM, Werneck-de-CastroJP, OliveiraKC, FernandesGW, FonsecaTL, NascimentoBP, McAninchEA, RicciE, Kvárta-PappZ, FeketeC, BernardiMM, GerebenB, BiancoAC, RibeiroMO. 2016. Type 2 deiodinase disruption in astrocytes results in anxiety-depressive-like behavior in male mice. Endocrinology, 157:3682–3695.
8.
MentucciaD, Proietti-PannunziL, TannerK, BacciV, PollinTI, PoehlmanET, ShuldinerAR, CeliFS. 2002. Association between a novel variant of the human type 2 deiodinase gene Thr92Ala and insulin resistance: evidence of interaction with the Trp64Arg variant of the beta-3-adrenergic receptor. Diabetes, 51:880–883.
9.
WoutersHJ, van LoonHC, van der KlauwMM, EldersonMF, SlagterSN, KoboldAM, KemaIP, LinksTP, van Vliet-OstaptchoukJV, WolffenbuttelBH. 2017. No effect of the Thr92Ala polymorphism of deiodinase-2 on thyroid hormone parameters, health-related quality of life, and cognitive functioning in a large population-based cohort study. Thyroid, 27:147–155.
10.
PanickerV, SaravananP, VaidyaB, EvansJ, HattersleyAT, FraylingTM, DayanCM. 2009. Common variation in the DIO2 gene predicts baseline psychological well-being and response to combination thyroxine plus triiodothyronine therapy in hypothyroid patients. J Clin Endocrinol Metab, 94:1623–1629.
11.
JoS, FonsecaTL, BoccoBMLC, FernandesGW, McAninchEA, BolinAP, Da ConceiçãoRR, Werneck-de-CastroJP, IgnacioDL, EgriP, NémethD, FeketeC, BernardiMM, LeitchVD, MannanNS, CurryKF, ButterfieldNC, BassettJHD, WilliamsGR, GerebenB, RibeiroMO, BiancoAC. 2019. Type 2 deiodinase polymorphism causes ER stress and hypothyroidism in the brain. J Clin Invest, 129:230–245.
McAninchEA, RajanKB, EvansDA, JoS, ChakerL, PeetersRP, BennettDA, MashDC, BiancoAC. 2018. A common DIO2 polymorphism and alzheimer disease dementia in African and European Americans. J Clin Endocrinol Metab, 103:1818–1826.
14.
StrommeP, GroenewegS, Lima de SouzaEC, ZevenbergenC, TorgersbråtenA, HolmgrenA, GurcanE, MeimaME, PeetersRP, VisserWE, Høneren JohanssonL, BabovicA, ZetterbergH, HeuerH, FrengenE, MisceoD, VisserTJ. 2018. Mutated thyroid hormone transporter OATP1C1 associates with severe brain hypometabolism and juvenile neurodegeneration. Thyroid, 28:1406–1415.
15.
MorshedSA, MaR, LatifR, DaviesTF. 2018. Biased signaling by thyroid-stimulating hormone receptor-specific antibodies determines thyrocyte survival in autoimmunity. Sci Signal, 11:eaah4120.
16.
DaiG, LevyO, CarrascoN. 1996. Cloning and characterization of the thyroid iodide transporter. Nature, 379:458–460.
17.
SmanikPA, RyuKY, TheilKS, MazzaferriEL, JhiangSM. 1997. Expression, exon-intron organization, and chromosome mapping of the human sodium iodide symporter. Endocrinology, 138:3555–3558.
18.
HaugenBR, AlexanderEK, BibleKC, DohertyGM, MandelSJ, NikiforovYE, PaciniF, RandolphGW, SawkaAM, SchlumbergerM, SchuffKG, ShermanSI, SosaJA, StewardDL, TuttleRM, WartofskyL. 2016. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid, 26:1–133.
19.
KogaiT, BrentGA. 2012. The sodium iodide symporter (NIS): regulation and approaches to targeting for cancer therapeutics. Pharmacol Ther, 135:355–370.
20.
WapnirIL, van de RijnM, NowelsK, AmentaPS, WaltonK, MontgomeryK, GrecoRS, DohánO, CarrascoN. 2003. Immunohistochemical profile of the sodium/iodide symporter in thyroid, breast, and other carcinomas using high density tissue microarrays and conventional sections. J Clin Endocrinol Metab, 88:1880–1888.
21.
TanMH, MesterJL, NgeowJ, RybickiLA, OrloffMS, EngC. 2012. Lifetime cancer risks in individuals with germline PTEN mutations. Clin Cancer Res, 18:400–407.
22.
FengF, YehiaL, NiY, ChangYS, JhiangSM, EngC. 2018. A nonpump function of sodium iodide symporter in thyroid cancer via cross-talk with PTEN signaling. Cancer Res, 78:6121–6133.
23.
FengF, YehiaL, EngC. 2019. Pro-tumorigenic non-pump function of sodium iodide symporter: a reimagined Trojan horse?. Oncotarget, 10:688–689.
24.
SpitzwegC, O'ConnorMK, BergertER, TindallDJ, YoungCY, MorrisJC. 2000. Treatment of prostate cancer by radioiodine therapy after tissue-specific expression of the sodium iodide symporter. Cancer Res, 60:6526–6530.
DelmoreJE, IssaGC, LemieuxME, RahlPB, ShiJ, JacobsHM, KastritisE, GilpatrickT, ParanalRM, QiJ, ChesiM, SchinzelAC, McKeownMR, HeffernanTP, VakocCR, BergsagelPL, GhobrialIM, RichardsonPG, YoungRA, HahnWC, AndersonKC, KungAL, BradnerJE, MitsiadesCS. 2011. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell, 146:904–917.
27.
ZhuX, ParkS, LeeWK, ChengSY. 2019. Potentiated anti-tumor effects of BETi by MEKi in anaplastic thyroid cancer. Endocr Relat Cancer [Epub ahead of print] DOI: 10.1530/ERC-19-0107.
